Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Delpacibart etedesiran by Avidity Biosciences for Myotonic Dystrophy: Likelihood of Approval
Delpacibart etedesiran is under clinical development by Avidity Biosciences and currently in Phase III for Myotonic Dystrophy. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Avidity Biosciences's Delpacibart etedesiran?
Delpacibart etedesiran is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase III program in Myotonic Dystrophy....
Risk adjusted net present value: What is the current valuation of Avidity Biosciences's Delpacibart etedesiran?
Delpacibart etedesiran is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Myotonic Dystrophy....